广东：支持放射性药物创新研发

Core Viewpoint - Guangdong Province is promoting the high-quality development of the nuclear medicine industry through a new action plan, focusing on the innovation and research of radioactive drugs [1] Group 1: Policy Support - The Guangdong Provincial Development and Reform Commission has issued an action plan for the years 2025-2030 to accelerate the development of the nuclear medicine industry [1] - The plan encourages enterprises, medical institutions, universities, and research institutes to increase investment in the research and development of new radioactive drugs with innovative targets, mechanisms, and types [1] Group 2: Research and Development Focus - There is a strong emphasis on enhancing the development of radiolabeled drugs, particularly those that are antibody-based, peptide-based, and small molecule-based [1] - The initiative aims to promote the production and application of highly specific diagnostic agents, radioactive therapeutic drugs, and integrated diagnostic and therapeutic drugs [1] Group 3: Domestic Production and Commercialization - The plan includes accelerating the domestic production and commercialization of significant radioactive drugs that are already available and clinically mature in foreign markets [1] - There is an active effort to attract domestic and international nuclear medicine companies to establish research centers, pilot platforms, and production bases for radioactive drug development in Guangdong Province [1]